US 10,889,647 B2
Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
Marie Chalons-Cottavoz, Lyons (FR); Mehdi Lahmar, Nantes (FR); Klaus Schwamborn, Nantes (FR); Nicola Beltraminelli, Lyons (FR); Stephanie Fallot, Lyons (FR); and Pierre Garrone, Lyons (FR)
Assigned to Forty Seven, Inc., Foster City, CA (US)
Appl. No. 16/68,874
Filed by Forty Seven, Inc., Foster City, CA (US)
PCT Filed Jan. 11, 2017, PCT No. PCT/EP2017/050508
§ 371(c)(1), (2) Date Jul. 9, 2018,
PCT Pub. No. WO2017/121771, PCT Pub. Date Jul. 20, 2017.
Claims priority of application No. 16150808 (EP), filed on Jan. 11, 2016; and application No. 16172651 (EP), filed on Jun. 2, 2016.
Prior Publication US 2019/0023784 A1, Jan. 24, 2019
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 21 Claims
 
1. An antibody that binds human CD47, comprising:
a) a VH-CDR1 sequence comprising the sequence set forth in SEQ ID NO:49, a VH-CDR2 sequence comprising the sequence set forth in SEQ ID NO:50, a VH-CDR3 sequence comprising the sequence set forth in SEQ ID NO:51, a VL-CDR1 sequence comprising the sequence set forth in SEQ ID NO:55, a VL-CDR2 sequence comprising the sequence set forth in SEQ ID NO:152, and a VL-CDR3 sequence comprising the sequence set forth in SEQ ID NO:57, wherein the CDR amino acids are according to Kabat; or
b) a VH-CDR1 sequence comprising the sequence set forth in SEQ ID NO:52, a VH-CDR2 sequence comprising the sequence set forth in SEQ ID NO:53, a VH-CDR3 sequence comprising the sequence set forth in SEQ ID NO:54, a VL-CDR1 sequence comprising the sequence set forth in SEQ ID NO:58, a VL-CDR2 sequence comprising the sequence set forth in SEQ ID NO:153, and a VL-CDR3 sequence comprising the sequence set forth in SEQ ID NO:60, wherein the CDR amino acids are according to IMGT;
c) a VH-CDR1 sequence comprising the sequence set forth in SEQ ID NO:49, a VH-CDR2 sequence comprising the sequence set forth in SEQ ID NO:50, a VH-CDR3 sequence comprising the sequence set forth in SEQ ID NO:51, a VL-CDR1 sequence comprising the sequence set forth in SEQ ID NO:55, a VL-CDR2 sequence comprising the sequence set forth in SEQ ID NO:56, and a VL-CDR3 sequence comprising the sequence set forth in SEQ ID NO:57, wherein the CDR amino acids are according to Kabat; or
d) a VH-CDR1 sequence comprising the sequence set forth in SEQ ID NO:52, a VH-CDR2 sequence comprising the sequence set forth in SEQ ID NO:53, a VH-CDR3 sequence comprising the sequence set forth in SEQ ID NO:54, a VL-CDR1 sequence comprising the sequence set forth in SEQ ID NO:58, a VL-CDR2 sequence comprising the sequence set forth in SEQ ID NO:59, and a VL-CDR3 sequence comprising the sequence set forth in SEQ ID NO:60, wherein the CDR amino acids are according to IMGT.